• Medientyp: E-Artikel
  • Titel: Chloral hydrate sedation for magnetic resonance imaging in newborn infants
  • Beteiligte: Finnemore, Anna; Toulmin, Hilary; Merchant, Naz; Arichi, Tom; Tusor, Nora; Cox, David; Ederies, Ash; Nongena, Phumza; Ko, Christopher; Dias, Ryan; Edwards, Anthony D.; Groves, Alan M.
  • Erschienen: Wiley, 2014
  • Erschienen in: Pediatric Anesthesia
  • Sprache: Englisch
  • DOI: 10.1111/pan.12264
  • ISSN: 1155-5645; 1460-9592
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Summary</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The aim of this study was to look for clinically significant adverse effects of chloral hydrate used in a large cohort of infants sedated for magnetic resonance imaging.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>Case notes of infants who underwent magnetic resonance imaging (<jats:styled-content style="fixed-case">MRI</jats:styled-content>) scanning from 2008 to 2010 were reviewed, with patient demographics, sedation dose, comorbidities, time to discharge, and side effects of sedation noted.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Four hundred and eleven infants (median [range] postmenstrual age per weight at scan 42 [31<jats:sup>+4</jats:sup>–60] weeks per 3500 g [1060–9900 g]) were sedated with chloral hydrate (median [range] dose 50 [20–80] mg·kg<jats:sup>−1</jats:sup>). In three cases (0.7%), desaturations occurred which prompted termination of the scan. One infant (0.2%) was admitted for additional observation following sedation but had no prolonged effects. In 17 (3.1%) cases, infants had desaturations which were self‐limiting or responded to additional inspired oxygen such that scanning was allowed to continue.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>When adhering to strict protocols, <jats:styled-content style="fixed-case">MRI</jats:styled-content> scanning in newborn infants in this cohort was performed using chloral hydrate sedation with a relatively low risk of significant adverse effects.</jats:p></jats:sec>